COLUMBIA UNIVERSITY MEDICAL CENTER

TAUB INSTITUTE for Research on Alzheimer's Disease and the Aging Brain

CLINICAL TRIALS

STUDY	WHO IS ELIGIBLE?
AMARANTH: An Efficacy and Safety Study of LY3314814 in Early Alzheimer's Disease. *The purpose of this study is to assess the efficacy and safety of LY3314814 compared with placebo administered for 104 weeks in the treatment of early Alzheimer´s disease.* Principal Investigator: Dr. Lawrence Honig	✓ Men and women between 55 and 85 years old. ✓ Diagnosed with mild Alzheimer's disease or mild cognitive impairment. ✓ Have a friend, relative or caregiver willing to be a study partner throughout the study. Websites: www.theamaranthstudy.com https://clinicaltrials.gov/show/NCT02245737
CREAD: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease. *This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD.* Principal Investigator: Dr. Lawrence Honig	✓ Men and women between 50 and 85 years old ✓ Diagnosed with mild Alzheimer's disease or symptoms of memory loss. ✓ Have a friend, relative or caregiver willing to be a study partner throughout the study. Websites: www.creadstudy.com https://clinicaltrials.gov/show/NCT02670083
STEADFAST: Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease. *This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 18 months.* Principal Investigator: Dr. Lawrence Honig	✓ Men and women at least 50 years of age ✓ Have been diagnosed with mild Alzheimer's disease ✓ Have been taking one or more of the following medications for at least 3 months: memantine (Namenda® or Ebixa®), galantamine (Razadyne® or Reminyl®), Aricept® or Exelon® ✓ Have a friend, relative or caregiver willing to be a study partner throughout the study. Websites: www.livingsteadfast.com https://clinicaltrials.gov/show/NCT02080364
A4: Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss. *The A4 study is investigating whether an investigational drug called solanezumab may reduce the impact of a protein known as "amyloid" or "beta amyloid" forming plaques in the brain and slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease).* Principal Investigator: Dr. Karen Bell	✓ Men and women between 65 and 85 years old. ✓ Normal thinking and memory abilities. ✓ Have a "study partner" (weekly contact who can answer questions once a year). Websites: www.A4study.org https://clinicaltrials.gov/show/NCT02008357

COLUMBIA UNIVERSITY MEDICAL CENTER

TAUB INSTITUTE for Research on Alzheimer's Disease and the Aging Brain

STUDY	WHO IS ELIGIBLE?
OLFACTION: Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly. *The purpose of this study is to evaluate if a change in one's ability to identify odors may predict improvement in patients with memory loss who are receiving a medicine called donepezil (also known as Aricept).* Principal Investigator: Dr. Devangere Devanand	✓ Men and women between 55 and 95 years old ✓ NOT taking the following medications: memantine (Namenda® or Ebixa®), galantamine (Razadyne® or Reminyl®), Aricept® or Exelon® Website: https://clinicaltrials.gov/show/NCT01951118
LITHIUM: Treatment of Psychosis and Agitation in Alzheimer's Disease. *The purpose of this study is to evaluate if treatment with the medication lithium is helpful in the treatment of difficulties in thinking and behavior in patients with memory disorders.* Principal Investigator: Dr. Devangere Devanand	✓ Men and women between 55 and 95 years old ✓ Have a diagnosis of Alzheimer's disease. ✓ Have symptoms of agitation or aggression Website: https://clinicaltrials.gov/show/NCT02129348
AVANIR: Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type. *The Avanir study will evaluate if treatment with the medication AVP-786 is helpful in the treatment of agitation secondary to Alzheimer's Disease.* Principal Investigator: Dr. Devangere Devanand	✓ Men and women between 50 and 90 years old ✓ Have a diagnosis of Alzheimer's disease. ✓ Have symptoms of agitation or aggression Website: https://clinicaltrials.gov/show/NCT02442778

For more information, please contact:

Betina Idnay, RN

Phone: (212) 342-5615; Email: bsi2102@cumc.columbia.edu